Utilization of calprotectin in axial spondyloarthropathies - a review
DOI:
https://doi.org/10.12775/JEHS.2025.81.59524Keywords
calprotectin, spondyloarthritis, axial spondyloarthritis, spondyloarthropathies, inflammatory bowel disease, calprotectin and spondyloarthropathies, arthritisAbstract
Introduction and purpose
Axial spondyloarthropathies represent a group of chronic inflammatory conditions that primarily affect the joints. Calprotectin, an inflammatory biomarker, is predominantly utilized in the context of inflammatory bowel diseases. This paper aims to explore the potential relationship between calprotectin levels and axial spondyloarthropathies, as well as to discuss how this correlation could be applied in clinical settings.
Description
Axial spondyloarthritis (axSpA) is a chronic inflammatory disorder that primarily impacts the sacroiliac joints and the spine, leading to symptoms such as inflammatory back pain and stiffness. The etiopathogenesis of axSpA is complex and multifactorial, involving genetic factors like HLA-B27 and immune system dysregulation. Recently, calprotectin has emerged as a significant inflammatory biomarker, showing promise in relation to axSpA. Elevated calprotectin levels have been associated with increased disease activity, indicating its potential utility in monitoring inflammation and influencing treatment strategies. Nevertheless, the precise role of calprotectin in the pathogenesis and progression of axSpA remains unclear, necessitating further research to establish its clinical relevance.
Summary
Although axial spondyloarthritis is a condition that can be effectively managed, its chronic nature, along with symptoms like inflammatory back pain and stiffness, can significantly affect the quality of life for patients and induce anxiety in patients and their families. The exploration of biomarkers such as calprotectin presents a promising opportunity for assessing disease activity and informing treatment strategies; however, its precise role remains unclear. Advancing research into calprotectin's involvement in axSpA is essential for developing innovative strategies for disease prevention, enhancing diagnostic accuracy, and deepening our understanding of the inflammatory mechanisms that underlie this condition.
References
1. Magrey MN, Danve AS, Ermann J, Walsh JA. Recognizing Axial Spondyloarthritis: A Guide for Primary Care. Mayo Clin Proc. 2020 Nov;95(11):2499-2508. doi: 10.1016/j.mayocp.2020.02.007. Epub 2020 Jul 29. PMID: 32736944
2. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017 Jul 1;390(10089):73-84. doi: 10.1016/S0140-6736(16)31591-4. Epub 2017 Jan 20. PMID: 28110981
3. Slobodin G, Eshed I. Non-Radiographic Axial Spondyloarthritis. Isr Med Assoc J. 2015 Dec;17(12):770-6. PMID: 26897981
4. Bowness P. HLA-B27. Annu Rev Immunol. 2015;33:29-48. doi: 10.1146/annurev-immunol-032414-112110. PMID: 25861975
5. George E Fragoulis, Stefan Siebert, Treatment strategies in axial spondyloarthritis: what, when and how?, Rheumatology, Volume 59, Issue Supplement_4, October 2020, Pages iv79–iv89, https://doi.org/10.1093/rheumatology/keaa435
6. Ayling RM, Kok K. Fecal Calprotectin. Adv Clin Chem. 2018;87:161-190. doi: 10.1016/bs.acc.2018.07.005. Epub 2018 Oct 1. PMID: 30342711
7. Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci. 2019 Aug;56(5):307-320. doi: 10.1080/10408363.2019.1619159. Epub 2019 Jun 6. PMID: 31088326
8. Kang, K., Park, S. H., & Hong, Y. (2020). Relationship between faecal calprotectin and inflammation in peripheral joints and entheses in axial spondyloarthritis. Scandinavian Journal of Rheumatology, 49(5), 397–404. https://doi.org/10.1080/03009742.2020.1748707
9. Gill T, Rosenbaum JT. Putative Pathobionts in HLA-B27-Associated Spondyloarthropathy. Front Immunol. 2021 Jan 18;11:586494. doi: 10.3389/fimmu.2020.586494. PMID: 33537028; PMCID: PMC7848169
10. Walsh JA, Magrey M. Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. J Clin Rheumatol. 2021 Dec 1;27(8):e547-e560. doi: 10.1097/RHU.0000000000001575. PMID: 33105312; PMCID: PMC8612900
11. van Gaalen FA, Rudwaleit M. Challenges in the diagnosis of axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101871. doi: 10.1016/j.berh.2023.101871. Epub 2023 Sep 14. PMID: 37714776
12. Fattorini F, Gentileschi S, Cigolini C, Terenzi R, Pata AP, Esti L, Carli L. Axial spondyloarthritis: one year in review 2023. Clin Exp Rheumatol. 2023 Nov;41(11):2142-2150. doi: 10.55563/clinexprheumatol/9fhz98. Epub 2023 Nov 14. PMID: 37965699
13. Poddubnyy D. Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. Rheumatology (Oxford). 2020 Oct 1;59(Suppl4):iv6-iv17. doi: 10.1093/rheumatology/keaa250. PMID: 33053191; PMCID: PMC7566535
14. Lyu X, Chen J, Gao X, Yang J. Emerging story of gut dysbiosis in spondyloarthropathy: From gastrointestinal inflammation to spondyloarthritis. Front Cell Infect Microbiol. 2022 Aug 22;12:973563. doi: 10.3389/fcimb.2022.973563. PMID: 36072223; PMCID: PMC9441705
15. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewé RBM, Van den Bosch FE, Boteva B, Bremander A, Carron P, Ciurea A, van Gaalen FA, Géher P, Gensler L, Hermann J, de Hooge M, Husakova M, Kiltz U, López-Medina C, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Nissen MJ, Pimentel-Santos FM, Poddubnyy D, Proft F, Rudwaleit M, Telkman M, Zhao SS, Ziade N, van der Heijde D. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21. PMID: 36270658
16. Baraliakos X, Gladman DD, Chakravarty SD, Gong C, Shawi M, Rampakakis E, Kishimoto M, Soriano ER, Mease PJ. BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies. Rheumatol Adv Pract. 2024 Apr 23;8(2):rkae058. doi: 10.1093/rap/rkae058. PMID: 38765190; PMCID: PMC11099656
17. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-1299. doi: 10.1002/acr.24025. Epub 2019 Aug 21. PMID: 31436026; PMCID: PMC6764857
18. Ducourau E, Rispens T, Samain M, Dernis E, Le Guilchard F, Andras L, Perdriger A, Lespessailles E, Martin A, Cormier G, Armingeat T, Devauchelle-Pensec V, Gervais E, Le Goff B, de Vries A, Piver E, Paintaud G, Desvignes C, Ternant D, Watier H, Goupille P, Mulleman D. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open. 2020 Jan;6(1):e001047. doi: 10.1136/rmdopen-2019-001047. Epub 2020 Jan 9. PMID: 31958280; PMCID: PMC7046954
19. Torgutalp M, Rios Rodriguez V, Proft F, Protopopov M, Verba M, Rademacher J, Haibel H, Sieper J, Rudwaleit M, Poddubnyy D. Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception Cohort. Arthritis Rheumatol. 2022 Sep;74(9):1515-1523. doi: 10.1002/art.42144. Epub 2022 Aug 5. PMID: 35437900
20. van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022 Nov;81(11):1515-1523. doi: 10.1136/ard-2022-222608. Epub 2022 Jul 4. PMID: 35788492; PMCID: PMC9606523
21. Gottlieb AB, Armstrong AW, FitzGerald O, Gladman DD. Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 Annual Meeting. J Rheumatol. 2023 Nov;50(Suppl 2):1-3. doi: 10.3899/jrheum.2023-0496. Epub 2023 Jul 7. PMID: 37419627
22. Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fernández-Ávila DG, FitzGerald O, Garg A, Gladman DD, Goel N, Helliwell PS, Husni ME, Jadon DR, Katz A, Laheru D, Latella J, Leung YY, Lindsay C, Lubrano E, Mazzuoccolo LD, Mease PJ, O'Sullivan D, Ogdie A, Olsder W, Palominos PE, Schick L, Steinkoenig I, de Wit M, van der Windt DA, Kavanaugh A; GRAPPA Treatment Recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022 Aug;18(8):465-479. doi: 10.1038/s41584-022-00798-0. Epub 2022 Jun 27. Erratum in: Nat Rev Rheumatol. 2022 Dec;18(12):734. doi: 10.1038/s41584-022-00861-w. PMID: 35761070; PMCID: PMC9244095
23. Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut. 2021 Oct;70(10):1978-1988. doi: 10.1136/gutjnl-2021-324855. Epub 2021 Jun 18. PMID: 34145045; PMCID: PMC8458070
24. Inciarte-Mundo J, Frade-Sosa B, Sanmartí R. From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Front Immunol. 2022 Nov 3;13:1001025. doi: 10.3389/fimmu.2022.1001025. PMID: 36405711; PMCID: PMC9672845
25. Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C, Finckh A, Gabay C, Nissen MJ; physicians of the Swiss Clinical Quality Management (SCQM) registry. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020 May 6;22(1):105. doi: 10.1186/s13075-020-02190-3. PMID: 32375861; PMCID: PMC7201559
26. Khaki-Khatibi F, Qujeq D, Kashifard M, Moein S, Maniati M, Vaghari-Tabari M. Calprotectin in inflammatory bowel disease. Clin Chim Acta. 2020 Nov;510:556-565. doi: 10.1016/j.cca.2020.08.025. Epub 2020 Aug 18. PMID: 32818491; PMCID: PMC7431395
27. Saviano A, Migneco A, Brigida M, Petruzziello C, Zanza C, Savioli G, Franceschi F, Ojetti V. Serum Calprotectin in the Evaluation of Gastrointestinal Diseases: An Ace up Your Sleeve? Medicina (Kaunas). 2024 May 5;60(5):762. doi: 10.3390/medicina60050762. PMID: 38792945; PMCID: PMC11123171
28. Lazzarotto ES, Vasco JFM, Führ F, Riedi CA, Filho NAR. Systematic review on fecal calprotectin in cystic fibrosis. J Pediatr (Rio J). 2023 Jan-Feb;99(1):4-10. doi: 10.1016/j.jped.2022.01.006. Epub 2022 May 3. PMID: 35523321; PMCID: PMC9875247
29. Carnazzo V, Redi S, Basile V, Natali P, Gulli F, Equitani F, Marino M, Basile U. Calprotectin: two sides of the same coin. Rheumatology (Oxford). 2024 Jan 4;63(1):26-33. doi: 10.1093/rheumatology/kead405. PMID: 37603715; PMCID: PMC10765140
30. Chen F, He Z, Wang C, Si J, Chen Z, Guo Y. Advances in the study of S100A9 in cardiovascular diseases. Cell Prolif. 2024 Aug;57(8):e13636. doi: 10.1111/cpr.13636. Epub 2024 Mar 19. PMID: 38504474; PMCID: PMC11294427
31. Huang J, Yin Z, Song G, Cui S, Jiang J, Zhang L. Discriminating Value of Calprotectin in Disease Activity and Progression of Nonradiographic Axial Spondyloarthritis and Ankylosing Spondylitis. Dis Markers. 2017;2017:7574147. doi: 10.1155/2017/7574147. Epub 2017 May 24. PMID: 28630526; PMCID: PMC5463132
32. Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in Inflammation. Front Immunol. 2018 Jun 11;9:1298. doi: 10.3389/fimmu.2018.01298. PMID: 29942307; PMCID: PMC6004386
33. Maksymowych WP. Biomarkers for Diagnosis of Axial Spondyloarthritis, Disease Activity, Prognosis, and Prediction of Response to Therapy. Front Immunol. 2019 Mar 7;10:305. doi: 10.3389/fimmu.2019.00305. PMID: 30899255; PMCID: PMC6416369
34. Turina MC, Yeremenko N, van Gaalen F, van Oosterhout M, Berg IJ, Ramonda R, Lebre CM, Landewé R, Baeten D. Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. RMD Open. 2017 Jan 11;3(1):e000319. doi: 10.1136/rmdopen-2016-000319. PMID: 28123777; PMCID: PMC5237766
35. Sagard J, Olofsson T, Mogard E, Marsal J, Andréasson K, Geijer M, Kristensen LE, Lindqvist E, Wallman JK. Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis. Arthritis Res Ther. 2022 Feb 12;24(1):42. doi: 10.1186/s13075-022-02733-w. PMID: 35151357; PMCID: PMC8840679
36. Ondrejčáková L, Gregová M, Bubová K, Šenolt L, Pavelka K. Serum biomarkers and their relationship to axial spondyloarthritis associated with inflammatory bowel diseases. Autoimmun Rev. 2024 Mar;23(3):103512. doi: 10.1016/j.autrev.2023.103512. Epub 2023 Dec 31. PMID: 38168574
37. Duran A, Kobak S, Sen N, Aktakka S, Atabay T, Orman M. Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. Bosn J Basic Med Sci. 2016 Jan 1;16(1):71-4. doi: 10.17305/bjbms.2016.752. PMID: 26773186; PMCID: PMC4765943
38. Port H, Holm Nielsen S, Frederiksen P, Madsen SF, Bay-Jensen AC, Sørensen IJ, Jensen B, Loft AG, Madsen OR, Østergaard M, Pedersen SJ. Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis-results from two randomized controlled trials. Arthritis Res Ther. 2023 Aug 25;25(1):157. doi: 10.1186/s13075-023-03132-5. PMID: 37626399; PMCID: PMC10463764
39. Levitova A, Hulejova H, Spiritovic M, Pavelka K, Senolt L, Husakova M. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Res Ther. 2016 Nov 25;18(1):275. doi: 10.1186/s13075-016-1180-1. PMID: 27887637; PMCID: PMC5124318
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Patrycja Tymoszuk, Agata Żak, Rafał Sierzpowski, Agnieszka Protasiuk, Bartosz Kasperek, Katarzyna Augustowska, Laura Loryś, Klaudia Klimczak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 226
Number of citations: 0
